colesterolo

The quick read

What's driving the attention

Interest rises in new treatments for cholesterol, psoriasis, and rare diseases recommended by EMA.

The European Medicines Agency (EMA) has recommended approval for 12 new drugs targeting cholesterol, psoriasis, and rare diseases. This development is significant as it may improve treatment options and health outcomes for millions of patients, especially given the burden of high 'bad' cholesterol linked to millions of deaths annually. People seek to understand the changes and impacts these new medicines could have on patient care and disease management.